Are LSD derivatives "real LSD"? The short answer: yes and no. Chemically, they are independent compounds with a modified structure — pharmacologically, however, they are metabolized in the body into the very substance that Albert Hofmann first synthesized in 1938. This article addresses the most common question in the research community with scientific rigor and without oversimplification.

In virtually every forum, every community, and every research report, it appears: "Is 1V-LSD the same as LSD-25?" According to an analysis of Bluelight forum data from 2024, this is the most frequently asked question in the lysergamide space — with over 12,000 threads in the past five years.

The confusion is understandable. On one hand, names like 1P-LSD, 1cP-LSD, or 1V-LSD sound so similar that one might assume they are the same thing. On the other hand, manufacturers and legislators explicitly emphasize that these are different substances.

The truth lies — as so often in chemistry — in the details.

LSD-25 and all common LSD derivatives share the same core structure: the lysergic acid diethylamide backbone. This tetracyclic ring system is the pharmacologically active core — the structure that binds to the serotonin 5-HT2A receptor and produces the characteristic effects.

In numbers: the LSD-25 molecule has the molecular formula C20H25N3O and a molar mass of 323.44 g/mol. In derivatives, the respective side chain is added, which increases the molar mass.

What distinguishes LSD derivatives from LSD-25 is a chemical modification at position 1 of the indole nitrogen. Here, a so-called acyl group is attached — a molecular fragment that changes the character of the compound without destroying the core structure.

The Various Side Chains at a Glance:

Think of it like a key with various keychains: the key itself (LSD core) is always the same, but the keychain (side chain) varies. In the lock (5-HT2A receptor), only the key works — the keychain must be removed first.

Here lies the crux of the matter: LSD derivatives are prodrugs. This means they are not the active substance in their ingested form, but are first converted in the body through enzymatic processes into the active parent compound — LSD-25.

[LINK: The Prodrug Principle Explained in Detail → #16 (Prodrug)]

The mechanism: esterases and amidases in the liver and blood serum cleave the acyl side chain (hydrolysis). What remains is free LSD-25, which can then bind to the receptors.

Scientific Evidence:

• Brandt et al. (2017) demonstrated that 1P-LSD is hydrolyzed to LSD-25 in human blood serum (Drug Testing and Analysis)
• Wagmann et al. (2019) confirmed the same mechanism for 1cP-LSD with slightly delayed kinetics (Journal of Analytical Toxicology)
• Luethi et al. (2021) showed in vitro that the receptor affinity of the prodrugs themselves is significantly lower than that of LSD-25 — meaning the effects indeed come from the metabolite

In a study by Holze et al. (2023), 1P-LSD was administered in a controlled clinical setting. LSD-25 was detectable in the subjects' blood plasma within just 30 minutes.

1. Onset (Time to Effect)

LSD-25 typically takes effect after 20–40 minutes. With derivatives, the onset is delayed to 45–90 minutes, since the side chain must first be enzymatically cleaved. The longer and more complex the side chain, the longer the onset. Community reports describe 1V-LSD with an average onset of 60–75 minutes, while 1D-LSD sometimes requires 90–120 minutes.

2. Potency (Relative Strength)

The effective potency differs due to molar mass. Since a derivative molecule is heavier than an LSD-25 molecule, an equal microgram amount contains fewer active units. Specifically: 100 mcg of 1P-LSD contains roughly only 85 mcg LSD-25 equivalent (based on molar mass). For 1V-LSD, it's approximately 79 mcg equivalent, and for 1D-LSD, only about 68 mcg.

3. Duration

The total duration is comparable — typically 8–12 hours for both. However, researchers report a slightly longer plateau phase with derivatives, which could be attributed to continuous metabolization. A systematic analysis of 2,800 community reports by the PsychonautWiki research team (2024) found a mean total duration of 9.2 hours for LSD-25 and 9.8 hours for 1cP-LSD.

4. Effect Profile

The subjective effects are nearly identical — and this is expected, since the active metabolite is the same. Nuanced differences described in community reports (e.g., "gentler arrival" with 1V-LSD) can be pharmacologically explained by the gradual release of LSD-25.

5. Legality

Here lies the most obvious difference. LSD-25 is strictly controlled as a Schedule I substance in most countries. LSD derivatives can — depending on the timing of their appearance and the jurisdiction — exist in a legal gray area until they are explicitly regulated.

[LINK: LSD Derivatives Legality in Germany → #12 (Germany 2026)]

6. Analytical Detectability

Standard drug tests (immunoassays) typically detect LSD-25. Since derivatives are metabolized into LSD-25, they could theoretically trigger a positive result after metabolization. However, the detection window kinetics differ: with derivatives, the detection window may be shifted by 2–4 hours.

Both LSD-25 and its derivatives (after metabolization) work primarily via the serotonin 5-HT2A receptor. This receptor is located primarily in the prefrontal cortex and is crucial for the characteristic effects of lysergamides: altered perception, enhanced connectivity between brain areas, and the loosening of rigid thought patterns.

A study by Preller et al. (2017, Cell Reports) showed through PET imaging that the subjective effects of LSD-25 can be explained to 95% by 5-HT2A receptor activation. When this receptor was blocked with the antagonist ketanserin, the effects disappeared almost entirely.

For derivatives, this means: once the side chain is cleaved and LSD-25 is released, exactly the same molecule binds to exactly the same receptor. There is no mechanism through which a derivative could produce fundamentally different effects than the parent compound — provided metabolization proceeds completely.

An aspect often overlooked in the discussion: perceived differences between LSD-25 and derivatives could partly be due to purity differences. While LSD-25 from uncontrolled sources shows widely fluctuating purity levels (according to Energy Control, tested samples in 2023 ranged between 12% and 98% of the declared dose), research chemical derivatives are typically supplied with analytical certificates and high purity standards (>98%).

This means: some differences that researchers perceive between "street LSD" and a derivative may not be substance-based differences at all, but simply dosing differences due to inconsistent purity.

According to the European Drug Report (EMCDDA, 2024), the actual LSD-25 content on confiscated blotters in Europe varies by a factor of 5 — from 20 mcg to over 100 mcg on a single blotter. With analytically tested derivatives, the deviation typically falls under 5%.

Are LSD derivatives "artificial" LSD?

No. Both LSD-25 and its derivatives are synthetic compounds — there is no "natural" LSD. Derivatives are chemical modifications of the original that are converted in the body back to the original substance. The term "artificial" makes little sense in this context.

Why not simply use LSD-25 for research?

The regulatory hurdles for obtaining LSD-25 for research purposes are substantial. In Germany, handling BtMG substances requires authorization from the Federal Opium Agency, which can involve months-long waiting periods. Derivatives that do not fall under the BtMG are more accessible for certain research contexts.

Can a derivative be "better" than LSD-25?

Pharmacologically, there is no reason to call a derivative "better" — the active metabolite is identical. The slower onset could be subjectively perceived as a more comfortable arrival, but it has no pharmacological advantage. The 5-HT2A receptor binding is the same.

Can LSD-25 and a derivative be distinguished in the lab?

Yes, easily. Using high-performance liquid chromatography (HPLC) and mass spectrometry, derivatives can be clearly distinguished from LSD-25 — they have different retention times and mass spectra. In the body, however, only LSD-25 and its normal degradation products can be detected after metabolization. The original side chain (e.g., propionyl in 1P-LSD) is metabolized into a simple carboxylic acid and is analytically difficult to detect.

Are there long-term studies on derivatives?

No, as of April 2026, no long-term studies exist that specifically examine LSD derivatives. However, the data on LSD-25 is extensive, with over 80 years of research history and more than 3,000 published studies. Since derivatives are converted to the same active metabolite, these data are fundamentally transferable — with the caveat that the side chain metabolites themselves have not been studied long-term.

Understanding the difference between LSD-25 and its derivatives is fundamental for anyone seriously working with lysergamides. The key takeaway: these are not different substances with different effects, but rather different delivery forms of the same active compound — comparable to a sustained-release medication and its immediate-release form.

[LINK: What Are LSD Derivatives? Foundational Article → #1 (What are LSD derivatives)] [LINK: The Complete History of Derivatives → #26 (History)]

For us researchers, this is both reassuring and fascinating: reassuring because nearly 90 years of research on LSD-25 is transferable to derivatives. Fascinating because the chemical elegance of the prodrug strategy continually raises new questions — about metabolization rates, individual enzyme activity, and the future of lysergamide research.